{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T05:34:27Z","timestamp":1784784867804,"version":"3.55.0"},"reference-count":31,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T00:00:00Z","timestamp":1583280000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Chronic lymphocytic leukemia (CLL) treatment has changed dramatically, and landscape of second hematologic malignancies (SHM) evolves in the new era of targeted therapy. No data were available about the real\u2010world burden of SHM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>All 2631 patients with CLL in the Cancer registry of Norway registered 2003\u20102012 were included.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After median follow\u2010up of 6.6\u00a0years, 103 patients (4%) developed SHM. Diffuse large B\u2010cell lymphoma (DLBCL) was most common (n\u00a0=\u00a065; 63%). Median survival was 9.3\u00a0years (95% CI; 8.9\u20109.8) in non\u2010SHM patients and 1.7\u00a0years in DLBCL, 0.8\u00a0years in Hodgkin lymphoma (n\u00a0=\u00a012), and 2.8\u00a0years in myeloid neoplasia (n\u00a0=\u00a015; 95% CI: 0.3\u20102.6, 0.6\u20102.9, and 0.4\u20105.3, respectively; <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a0.001). Outcomes were poorest for SHM patients treated for CLL (HR 2.76, 95% CI 1.4\u20105.5, <jats:italic>P<\/jats:italic> = 0.003). A higher proportion of men and younger age were found in SHM patients (median age 66 vs 72\u00a0years in non\u2010SHM; <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a0.001; men 68% vs 57%, <jats:italic>P<\/jats:italic>\u00a0=\u00a0.03). Myeloid neoplasia was rare (incidence rate 1\/1000 person\u2010years; 95% CI: 0.6\u20101.5) and tended to occur later than DLBCL in patients treated for CLL (median time from CLL to SHM 62 vs 45\u00a0months; <jats:italic>P<\/jats:italic>\u00a0=\u00a0.09).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>SHM and especially myeloid malignancies were rare in chemoimmunotherapy era.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.13396","type":"journal-article","created":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T13:59:16Z","timestamp":1581688756000},"page":"546-553","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Chronic lymphocytic leukemia and secondary hematological malignancies: A nation\u2010wide cancer registry study"],"prefix":"10.1111","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8166-4404","authenticated-orcid":false,"given":"Andrea","family":"Lenartova","sequence":"first","affiliation":[{"name":"Department of Hematology Oslo University Hospital Oslo Norway"},{"name":"Institute of Clinical Medicine Faculty of Medicine University of Oslo Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom B\u00f8rge","family":"Johannesen","sequence":"additional","affiliation":[{"name":"The Cancer Registry of Norway Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geir Erland","family":"Tj\u00f8nnfjord","sequence":"additional","affiliation":[{"name":"Department of Hematology Oslo University Hospital Oslo Norway"},{"name":"Institute of Clinical Medicine Faculty of Medicine University of Oslo Oslo Norway"},{"name":"K.G.Jebsen Centre for B\u2010Cell Malignancies University of Oslo Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,3,4]]},"reference":[{"key":"e_1_2_13_2_1","unstructured":"Cancer Stat Facts[Internet].2019.https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html. Accessed May 25 2019."},{"key":"e_1_2_13_3_1","volume-title":"Cancer in Norway 2016 \u2013 Cancer Incidence, Mortality Survival and Prevalene in Norway","author":"Cancer Registry of Norway","year":"2017"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.849"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.313"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.1112"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-342485"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-140582"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.08.128"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.218"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13262"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.381"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0237-1"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24930"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.13714"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.227"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2019.04.002"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.1811"},{"issue":"18","key":"e_1_2_13_19_1","first-page":"2056","article-title":"Chronic lymphocytic leukaemia in Norway\u2013incidence and prognostic markers at diagnosis","volume":"132","author":"Tjonnfjord GE","year":"2012","journal-title":"Tidsskr Nor Laegeforen"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22570"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-134858"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.06.033"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199805213382104"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2016.1154956"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313984"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.33"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.0890"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-516229"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713976"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30788-5"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61381-5"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1213831"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.13396","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13396","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.13396","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13396","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T01:40:07Z","timestamp":1694050807000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,4]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["10.1111\/ejh.13396"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13396","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,4]]},"assertion":[{"value":"2019-12-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}